StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

60 Degrees Pharmaceuticals Gets Nasdaq Delisting Notice, Plans Reverse Split

60 Degrees Pharmaceuticals said Nasdaq staff moved to delist its stock after it closed below $1 for 30 trading days and was ineligible for a compliance period because of two prior reverse splits. The company has appealed and plans a reverse split on December 2, 2026.

What happened

60 Degrees Pharmaceuticals, Inc., a Washington, D.C.-based drug developer whose common stock (SXTP) and warrants (SXTPW) trade on the Nasdaq Capital Market, said on November 19, 2026 it received a letter from Nasdaq's Listing Qualifications Department notifying it that it had failed the exchange's minimum bid price rule.

According to the 8-K, the company's listed securities closed below $1.00 per share over the previous 30 consecutive business days, from October 8 through November 18, 2026. That is the threshold in Nasdaq Listing Rule 5550(a)(2).

Nasdaq staff also determined the company is not eligible for a compliance period. The filing states the company did a 1-for-5 reverse stock split on February 24, 2025 and a 1-for-4 reverse stock split on January 20, 2026 — a cumulative 1-for-20 ratio — and that under Rule 5810(c)(3)(A)(iv) a company that has done a reverse split in the prior year gets no cure period. Staff therefore moved to delist the securities.

The company said it has requested a hearing before a Nasdaq Hearings Panel and paid the $20,000 hearing fee. That request stays any suspension of trading and the filing of a Form 25-NSE, the form that would remove the securities from Nasdaq listing and registration, until the Panel rules.

Separately, the company said it has confirmed with Nasdaq that it will do another reverse stock split, expected to take effect December 2, 2026. The stock would trade split-adjusted under the same SXTP symbol and a new CUSIP number. The company said the ratio and treatment of fractional shares will be disclosed before it takes effect, and that it intends to present the split to the Panel as its plan to regain compliance.

The filing includes no assurance that the Panel will grant continued listing, that the split will occur on the expected date, or that the post-split price will stay above $1.00.

The company's shares closed at $0.4682 on the event date, down 6.36% from the prior close of $0.50, according to the price data.

What this means

Nasdaq's minimum bid price rule requires a listed stock to trade at $1.00 or more. When it closes below that for 30 straight business days, the exchange sends a deficiency notice. Normally a company gets 180 calendar days to fix it, usually by getting the price back up. Nasdaq Listing Rule 5810(c)(3)(A)(iv) removes that cushion for companies that have already done a reverse split within the past year, which is the situation Nasdaq says applies here given the February 2025 and January 2026 splits.

A reverse stock split is the opposite of the familiar split. It combines shares: in a 1-for-5 split, five old shares become one new share, and the price per share rises roughly fivefold while the number of shares falls. The company's stated purpose here is arithmetic — to lift the per-share bid above $1.00 — not to change the value of anyone's stake in the business.

Item 3.01 of Form 8-K is the item companies use to disclose a delisting notice or a failure to meet a continued listing standard. Item 7.01 is a Regulation FD disclosure, used to release information to the market broadly so it is not selectively shared; the filing says the company is using it to publish the Nasdaq letter as required by Nasdaq Rule 5810(b). Item 8.01 covers other events, here the reverse split plan.

The appeal process moves the decision to a Hearings Panel, which will ask the company for a plan to regain compliance and can include a commitment to do a reverse split. A hearing request pauses the clock: trading continues and the Form 25-NSE is not filed while the Panel considers the case. If the Panel rules against the company, or if no appeal had been filed by the November 27, 2026 deadline, the securities would be suspended at the open on December 1, 2026 and the Form 25-NSE would be filed.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.